Immunocore (IMCR) reported Wednesday its Q4 net loss widened to $0.47 per diluted share, from a loss of $0.40 a year earlier.

Analysts polled by FactSet expected a loss of $0.24.

Revenue for the quarter ended Dec. 31 was $84.1 million, up from $70.2 million a year earlier.

Analysts surveyed by FactSet expected $84.5 million.

As of Dec. 31, the company said it had $820.4 million in cash, cash equivalents and marketable securities.

Immunocore's shares were down over 4% in recent premarket activity.